Banfi Cristina, Piarulli Francesco, Ragazzi Eugenio, Ghilardi Stefania, Greco Arianna, Lapolla Annunziata, Sartore Giovanni
Unit of Functional Proteomics, Metabolomics and Network Analysis, Centro Cardiologico Monzino IRCCS, 20138 Milan, Italy.
Department of Medicine-DIMED, University of Padova, 35122 Padova, Italy.
Life (Basel). 2024 Jul 17;14(7):886. doi: 10.3390/life14070886.
Different specific surfactant proteins (SPs) have been associated with various pathological conditions, not only of the respiratory system, but also more recently with cardiovascular diseases, such as heart failure. The aim of the present study was to evaluate the role of SP-A, SP-D, and the precursor protein of SP-B (proSP-B) in the pathogenesis of cardiovascular damage in patients affected by type 2 diabetes (T2D).
The study considered 31 patients with T2D (DN group), 34 patients with both T2D and coronary heart disease (CHD) (DC group), and 30 patients without diabetes but with a diagnosis of CHD (NC group). SP-A, SP-D, and proSP-B concentrations were determined in plasma samples, and were statistically compared using parametric and multivariate methods.
Higher plasma concentrations of SP-D and proSP-B were found in patients affected by both T2D and CHD (DC group), and in patients with CHD without diabetes (NC group), in comparison to T2D patients (DN group). A significant correlation, both with linear regression ( = 0.3565, = 0.001) and Principal Component Analysis (PCA), was found between the plasma levels of SP-D and proSP-B in the overall cohort of patients. No differences in SP-A were observed among the three groups of subjects.
The present study extends the knowledge on the role of plasma SPs' levels as possible indicators of the risk of CHD being linked to T2D disease progression.
不同的特定表面活性蛋白（SPs）与多种病理状况相关，不仅涉及呼吸系统，而且最近还与心血管疾病如心力衰竭有关。本研究的目的是评估SP-A、SP-D和SP-B前体蛋白（proSP-B）在2型糖尿病（T2D）患者心血管损伤发病机制中的作用。
该研究纳入了31例T2D患者（糖尿病肾病组）、34例同时患有T2D和冠心病（CHD）的患者（糖尿病合并冠心病组）以及30例无糖尿病但诊断为CHD的患者（非糖尿病冠心病组）。测定血浆样本中SP-A、SP-D和proSP-B的浓度，并使用参数和多变量方法进行统计学比较。
与T2D患者（糖尿病肾病组）相比，同时患有T2D和CHD的患者（糖尿病合并冠心病组）以及无糖尿病的CHD患者（非糖尿病冠心病组）血浆中SP-D和proSP-B的浓度更高。在整个患者队列中，SP-D和proSP-B的血浆水平之间通过线性回归（r = 0.3565，P = 0.001）和主成分分析（PCA）均发现显著相关性。三组受试者之间未观察到SP-A的差异。
本研究扩展了关于血浆SPs水平作为与T2D疾病进展相关的CHD风险可能指标作用的认识。
